Cochrane Critique Clears Eight Days as the FDA and CMS Stay Out of the Record
Eight days after Cochrane called anti-amyloid efficacy trivial, neurologists split between trial-mixing artifact and class failure — and neither the FDA nor CMS has moved.
The news. The narrative. The timeline.
Bureau: Chicago
Eight days after Cochrane called anti-amyloid efficacy trivial, neurologists split between trial-mixing artifact and class failure — and neither the FDA nor CMS has moved.
The Journal of the American College of Radiology editorialized Wednesday that helium should be relisted as a strategic material — the shortage is now a security designation ask.
The state veterinarian says the strain is not coming from migratory birds — 'Dairy cattle are giving it to other dairy cattle' — and most infected animals are asymptomatic.
Thursday's MMWR issue 15 did not center the 1,748-case measles outbreak or bovine H5N1 — the silence the paper flagged Tuesday has resolved as policy, not editorial lag.
The CDC's Thursday dashboard carries the 1,748-case number into a second week; HHS has not revised Kennedy's April 17 Mexico comparison.
FDA's January request to strip SI/B language from Saxenda, Wegovy, and Zepbound labels is propagating through filings as NME approvals accelerate.
The dormant LaGuardia thread reactivates with a legible datum: a controller cleared the fire truck to cross twelve seconds before the Air Canada Express jet touched down.
The four NEST figures hold into Day Two with no administration counter-proposal and no Vance family event on the calendar.
Nine days after publication, the Venegas-Sanabria paper's finding — loneliness sets a memory floor, not a trajectory — has accumulated no peer commentary and no institutional rebuttal.
Entrant demographics list 21 runners aged 80 and older; cohort-level BAA and BIDMC medical-tent outcomes have not been released as transparency pressure builds.